Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

imaging study

- PMLiVE

Johnson & Johnson to expand cardiovascular capabilities with $13.1bn Shockwave acquisition

Cardiovascular disease results in an estimated 17.9 million global deaths every year

- PMLiVE

Study reveals early menopause and higher CVD risk could be linked to cognitive decline

Approximately 733,040 people in Canada are estimated to be living with dementia

Biogen Idec building

Biogen receives EC approval for Skyclarys in Friedreich’s ataxia patients

The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals

- PMLiVE

UK Biobank reveals new data from world’s largest genetic project

The data will accelerate the development of potentially lifesaving treatments and cures

- PMLiVE

Merck to acquire Caraway Therapeutics in a deal worth up to $610m

The deal gives Merck access to a pipeline of therapeutics for neurodegenerative and rare diseases

- PMLiVE

New report identifies key issues with NICE’s methods for evaluating Alzheimer’s drugs

Several disease-modifying treatments for use in Alzheimer's disease are at varying stages of development and regulatory approval

- PMLiVE

Bristol Myers Squibb’s Camzyos recommended by NICE for inherited heart condition

One in 500 people in the UK are affected by hypertrophic cardiomyopathy

- PMLiVE

Alzheimer’s Research UK calls on party leaders to tackle dementia pressures

One in three people living with dementia in England never receive a formal diagnosis

- PMLiVE

New dementia risk score ‘calculator’ shown to strongly identify disease risk

Targeting key risk factors could potentially avert around 40% of dementia cases

- PMLiVE

Quest Diagnostics launches Alzheimer’s blood test for US consumers

Alzheimer's disease is expected to affect around 14 million people in the US by 2060

- PMLiVE

UK experts and politicians meet to discuss challenges faced by progressive MS patients

Primary-progressive MS accounts for approximately 10-15% of multiple sclerosis cases

- PMLiVE

World Health Organization publishes updated essential medicines list

Three medicines that can delay or slow MS disease progression have been included in the EML

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links